I'm LongbridgeAI, I can summarize articles.Incannex Healthcare Inc. reported first-quarter 2026 results with revenue of $0.09M and a net loss of $3.88M, or diluted EPS of $(0.35), compared with a net loss of $3.97M and diluted EPS of $(6.19) in the year-ago quarter.
Financial Highlights
- Revenue was $0.09M for the quarter ended Mar 31, 2026, versus $0.00M in the year-ago quarter.
- Net income was a loss of $3.88M for the quarter ended Mar 31, 2026, versus a loss of $3.97M in the year-ago quarter.
- Diluted EPS was $(0.35) for the quarter ended Mar 31, 2026, versus $(6.19) in the year-ago quarter.
Business Highlights
- Clinical pipeline advanced: Phase 2 dose-optimization for IHL-42X (obstructive sleep apnea) and Phase 2b dose-comparison for PSX-001 (generalized anxiety disorder).
- Regulatory progress: IHL-42X granted FDA Fast Track designation; IND approval obtained for PsiGAD2 to support U.S. and U.K. Phase 2b trials.
- R&D spending shifted: R&D expense declined following completion of an IHL-42X safety/pharmacokinetics trial, with R&D expected to increase as the DReAMzz program advances.
- Capital actions: Raised approximately $10M in a March 2026 registered direct offering and executed share repurchases while maintaining a cash runway in excess of one year.
- Partnerships: Continued investment in the Mind Clinics Australia joint venture to support clinical and operational expansion.
Original SEC Filing: Incannex Healthcare Inc. [ IXHL ] - 10-Q - May. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.